-
公开(公告)号：US20140242625A1
公开(公告)日：2014-08-28
申请号：US14275055
申请日：2014-05-12
Applicant: UCB PHARMA, S.A.
Inventor： BRYAN JOHN SMITH , HELEN MARIE KIRKE
IPC: C12Q1/37
CPC classification number: C12Q1/37 , G01N33/6857 , G01N2333/96433
Abstract: A method of measuring acidic species generated by degradation of a Fab or Fab′ component of a Fab-PEG or a Fab′-PEG is provided. The method involves: a) cleaving PEG and a linker from the Fab-PEG or Fab′-PEG with an enzyme; b) optionally separating the PEG and linker from the Fab or Fab′ to provide isolated Fab or Fab′; and c) quantitatively analyzing acidic species associated with the cleaved Fab or Fab′ and/or the cleaved PEG.
Abstract translation: 提供了测量由Fab-PEG或Fab'-PEG的Fab或Fab'成分降解而产生的酸性物质的方法。 该方法包括：a）用酶切割PEG和Fab-PEG或Fab'-PEG的接头; b）任选地将PEG和接头与Fab或Fab'分离以提供分离的Fab或Fab'; 和c）定量分析与切割的Fab或Fab'和/或切割的PEG相关的酸性物质。
-
公开(公告)号：US20140024077A1
公开(公告)日：2014-01-23
申请号：US13928458
申请日：2013-06-27
Applicant: UCB Pharma S.A.
Inventor： Richard Evan Gelinas , Mitra Choudhury Singhal , Yi Zhang , Andrew George Popplewell , Ralph Adams
IPC: C07K16/24
CPC classification number: A61K39/3955 , A61K2039/505 , C07K16/248 , C07K2316/96 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12N15/11
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Abstract translation: 本发明涉及对IL-6的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途以及产生所述抗体分子的方法。
-
23.发明授权公开(公告)号：US08617847B2
公开(公告)日：2013-12-31
申请号：US13632702
申请日：2012-10-01
Applicant: UCB Pharma S.A.
Inventor： Ralph Adams , Andrew George Popplewell , Stephen Edward Rapecki
IPC: C12P21/08
CPC classification number: C07K16/468 , A61K39/3955 , C07K16/244 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Abstract translation: 本发明涉及对IL-17A和IL-17F的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途和产生所述抗体分子的方法。
-
公开(公告)号：US20130243772A1
公开(公告)日：2013-09-19
申请号：US13672077
申请日：2012-11-08
Applicant: UCB PHARMA S.A.
Inventor： Ralph Adams , Pallavi Bhatta , Sam Phillip Heywood , David Paul Humphreys
CPC classification number: C07K16/18 , A61K39/3955 , A61K2039/505 , C07K16/2866 , C07K16/2878 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/624 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Abstract translation: 本发明涉及对人OX40的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途以及产生所述抗体分子的方法。
-
公开(公告)号：US20130102030A1
公开(公告)日：2013-04-25
申请号：US13632702
申请日：2012-10-01
Applicant: UCB PHARMA S.A.
Inventor： Ralph Adams , Andrew George Popplewell , Stephen Edward Rapecki
IPC: C07K16/46
CPC classification number: C07K16/468 , A61K39/3955 , C07K16/244 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Abstract translation: 本发明涉及对IL-17A和IL-17F的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途和产生所述抗体分子的方法。
-
Patent Agency Ranking
公开(公告)号：US10421816B2
公开(公告)日：2019-09-24
申请号：US15165131
申请日：2016-05-26
Applicant: UCB PHARMA S.A.
Inventor： Ralph Adams , Emma Dave , David Paul Humphreys
Abstract: The present invention provides a multivalent antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a constant region fragment, said constant region fragment located between two variable domains which are not a cognate pair, the heavy chain further comprising an Fc region with at least one domain selected from CH2, CH3 and combinations thereof, with the proviso that the heavy chain contains no more than one CH1 domain and only contains two variable domains, and a light chain comprising a constant region fragment located between two variable domains which are not a cognate pair, wherein said heavy and light chains are aligned to provide a first binding site formed by a first cognate pair of variable domains and a second binding site formed by a second cognate pair of variable domains.
-
公开(公告)号：US20190135909A1
公开(公告)日：2019-05-09
申请号：US16248845
申请日：2019-01-16
Applicant: UCB PHARMA, S.A.
Abstract: The present invention relates to a process for the purification of an antibody fragment from a periplasmic cell extract comprising a first cation exchange chromatography step and a second anion exchange chromatography step.
-
公开(公告)号：US10100130B2
公开(公告)日：2018-10-16
申请号：US15792373
申请日：2017-10-24
Applicant: UCB PHARMA S.A.
Inventor： David Paul Humphreys , Emma Dave , Laura Griffin , Sam Philip Heywood
Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
-
公开(公告)号：US09957328B2
公开(公告)日：2018-05-01
申请号：US15667649
申请日：2017-08-03
Applicant: UCB PHARMA, S.A.
Inventor： Mark Ellis , David Paul Humphreys
CPC classification number: C07K16/2875 , C07K2317/14 , C07K2317/55 , C12N9/90
Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising an expression vector comprising a recombinant polynucleotide encoding DsbC and one or more polynucleotides encoding an antibody or an antigen-binding fragment thereof specifically binding to CD154.
-
公开(公告)号：US20180072801A1
公开(公告)日：2018-03-15
申请号：US15492782
申请日：2017-04-20
Applicant: UCB PHARMA, S.A.
Inventor： David G. Winkler , Jiye Shi , John Latham
CPC classification number: C07K16/22 , A61K47/643 , A61K47/646 , C07K14/475 , C07K14/51 , C07K16/18 , C07K2317/76 , G01N33/6854 , G01N2333/4704
Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
-
-
-
-
-
-
-
-
-
Search Results
124
records
(took 0.019 seconds)
